文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

18F-DCFPyL PSMA PET在RefleXion X1子系统中的首次人体前瞻性初步研究

A Prospective First-In-Human Pilot Study 18F-DCFPyL Prostate-Specific Membrane Antigen Imaging on the RefleXion X1 Positron Emission Tomography-Computed Tomograpghy Subsystem in Patients with Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2025-09-15

本研究在20例前列腺癌患者中评估RefleXion X1放疗系统PET成像子系统检测18F-DCFPyL PSMA PET信号的能力,作为生物学引导放疗(BgRT)的基础。18例患者肿瘤在RefleXion X1 PET上可视化,8例(40%)BgRT计划可行且满足SBRT器官剂量约束,12例(60%)因靶区活性浓度低、归一化靶信号低或肿瘤邻近膀胱而不可行。

要点

  • RefleXion X1 PET子系统可在多数患者中可视化18F-DCFPyL PSMA PET avid肿瘤。
  • 仅40%患者BgRT计划可行并满足SBRT器官剂量约束。
  • 靶区活性浓度<5 kBq/mL或归一化靶信号<2.7是BgRT不可行的主要原因。

核心结论

  • 首次证明在前列腺癌患者中使用18F-DCFPyL PSMA PET成像进行RefleXion X1系统BgRT计划是可行的。

研究设计与样本

  • 前瞻性首次人体初步研究,患者先接受标准诊断性18F-DCFPyL PSMA PET扫描,若发现至少1个PET avid肿瘤则再在RefleXion X1设备上扫描。
  • 共20例患者纳入BgRT计划,确定靶体积、活性浓度和归一化靶信号并执行BgRT计划。

主要发现

  • 20例患者中识别出至少1个PSMA PET avid肿瘤用于BgRT计划:5个淋巴结转移、7个骨转移、7个前列腺腺体、1个前列腺床。
  • 18例患者的PET avid肿瘤在RefleXion X1 PET扫描上可视化,2例因肿瘤太靠近膀胱内PET活性而无法清晰可视化。
  • 8例(40%)患者BgRT计划可行并满足立体定向体部放疗器官剂量约束(3个前列腺腺体、3个骨、2个淋巴结)。
  • 12例(60%)患者BgRT不可行,原因包括靶区活性浓度低(<5 kBq/mL)、归一化靶信号强度低(<2.7)或PET avid肿瘤邻近膀胱。

关键数值与推荐

  • 靶区活性浓度<5 kBq/mL被列为BgRT不可行的原因之一。
  • 归一化靶信号强度<2.7被列为BgRT不可行的原因之一。
  • BgRT计划可行性以是否满足立体定向体部放疗器官剂量约束为判定标准。

临床怎么用

  • 对前列腺癌患者可先行标准诊断性18F-DCFPyL PSMA PET,若存在PET avid肿瘤可考虑在RefleXion X1上评估BgRT计划可行性。
  • 靶区活性浓度<5 kBq/mL或归一化靶信号<2.7时BgRT计划可能不可行。
  • 肿瘤邻近膀胱内PET活性可能影响RefleXion X1 PET可视化及BgRT计划。

局限性

  • 本研究为初步性首次人体研究,样本量为20例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The RefleXion X1 Medical Radiotherapy System (RefleXion Medical) is a novel radiation therapy (RT) device capable of delivering real-time positron emission tomography (PET) scan-guided or biology-guided RT (BgRT). The purpose of this pilot study was to evaluate the performance of its PET imaging subsystem to detect 2-(3-{1-carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyl) prostate-specific membrane antigen [PSMA] PET scan signal as the foundation for BgRT in patients with prostate cancer. METHODS AND MATERIALS: Patients underwent a standard diagnostic 18F-DCFPyl PSMA PET scan. If at least 1 PET-scan-avid tumor was identified, the patient was then scanned on the RefleXion X1 unit. The target volume, activity concentration, and normalized target signal were determined, and BgRT planning was performed. RESULTS: In 20 patients, at least 1 PSMA PET-scan-avid tumor was identified for BgRT planning (5 lymph node metastases, 7 bone metastases, 7 prostate glands, and 1 prostate bed). In 18 patients, the PET-scan-avid tumor was visualized on the RefleXion X1 PET scan, whereas in 2 patients, the tumor was too close to the PET scan activity in the bladder to be clearly visualized. BgRT planning was feasible and met stereotactic body RT organ dose constraints in 8 (40%) patients (3 prostate glands, 3 bones, and 2 lymph nodes). BgRT was not feasible in 12 (60%) patients because of low target activity concentration (<5 kBq/mL), low normalized target signal intensity (<2.7), or proximity of the PET-scan-avid tumor to the bladder. CONCLUSIONS: This is the first study to demonstrate the feasibility of using 18F-DCFPyl scan imaging for BgRT planning on the RefleXion X1 system in patients with prostate cancer. BgRT using targeted PET scan radiopharmaceuticals to guide RT represents a promising new dimension in radiation oncology and warrants further investigation.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Liu B, Dandapani S, Li Y, et al. A Prospective First-In-Human Pilot Study 18F-DCFPyL Prostate-Specific Membrane Antigen Imaging on the RefleXion X1 Positron Emission Tomography-Computed Tomograpghy Subsystem in Patients with Prostate Cancer. Adv Radiat Oncol. 2025. PMID: 41211608. doi:10.1016/j.adro.2025.101902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。